Artificial intelligence is becoming an increasingly important tool for drug discovery, with major pharmaceutical companies expanding AI collaborations across oncology and immunology. VERAXA Biotech has partnered with AI-focused contract research organization Ardigen to strengthen discovery efforts for its BiTAC(R) cancer therapy platform. The collaboration aims to identify optimal dual-target combinations for T-cell engagers and antibody-drug conjugates while reducing development risks.
VERAXA’s Boolean “AND-gated” BiTAC(R) technology presents a use case that may be particularly well suited for AI-assisted target selection and therapeutic design. AI analysis of historical clinical and preclinical datasets could help identify promising targets that were previously abandoned because of safety concerns. The partnership reflects a broader trend toward combining computational biology with next-generation antibody therapeutics to improve research productivity.
Artificial intelligence is becoming an increasingly important component of pharmaceutical research, with companies using machine learning to analyze complex biological data, identify drug targets and improve clinical development decisions. Against that backdrop, VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, announced a collaboration with AI-focused research partner Ardigen that is intended to strengthen development of the company’s BiTAC(R) oncology platform through AI-enabled target discovery and validation (https://ibn.fm/yoDH5).
The agreement brings together VERAXA’s antibody engineering capabilities with Ardigen’s expertise in artificial intelligence, computational biology and bioinformatics. Ardigen, headquartered in Kraków, Poland, with U.S. operations in San Francisco, has supported more than 700 discovery projects for clients. The partnership is expected to accelerate the identification of viable dual-target combinations for VERAXA’s BiTAC platform, potentially improving the success rate of its pipeline candidates.
This announcement underscores the growing reliance on AI to address longstanding challenges in oncology drug development, such as high attrition rates and safety issues. By leveraging machine learning to mine vast datasets, companies like VERAXA aim to revive previously abandoned targets and design therapies with greater precision. The collaboration also highlights how smaller biotech firms are increasingly turning to specialized AI partners to compete with larger pharmaceutical players in the race to develop next-generation cancer treatments.
For VERAXA, the partnership could be pivotal in advancing its BiTAC technology, which is designed to engage T-cells more selectively against tumor cells while minimizing off-target effects. If successful, the AI-driven approach may reduce the time and cost associated with early-stage discovery, ultimately bringing more effective therapies to patients faster.
